TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05680675

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single-Tracer FDG PET/CT Exam
Description: The PET technologist will administer approximately 15 millicuries (mCi) of FDG intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single-Tracer FDG PET/CT Exam
Description: The PET technologist will administer approximately 15 millicuries (mCi) of FDG intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single-Tracer FDG PET/CT Exam
Description: The PET technologist will administer approximately 15 millicuries (mCi) of FDG intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single-Tracer Cu64-DOTATATE PET/CT Exam
Description: The PET technologist will administer with approximately 4 mCi Cu64-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single-Tracer Ga68-DOTATATE PET/CT Exam
Description: The PET technologist will administer with with approximately 5 mCi Ga68-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single-Tracer PSMA PET/CT Exam
Description: The PET technologist will administer with with approximately 7 mCi Ga68-PSMA-11 intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images.
Study: NCT06275425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with Byfavo
Description: General anesthesia is maintained with intravenous continuous administration of Byfavo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation anesthesia with Sevoflurane
Description: General anesthesia is maintained with Sevoflurane.
Study: NCT04741802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TOPS
Description: weight loss program (Take Off Pounds Sensibly, TOPS) for overweight and obese African American breast cancer survivors in the local chapter of a national African American breast cancer support group (Sisters Network Triangle North Carolina, SNTNC).
Study: NCT05960383

Intervention type: DIAGNOSTIC_TEST
Intervention: BioFire Pneumonia Panel Plus
Description: Assessment of sensbility and specificity of BioFire Pneumonia Panel Plus in lung transplantation
Study: NCT06163352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: The sample consisted of all medical and surgical patients over 18 who do not have pressure injury upon admission and received one or more vasopressor agent infusions (norepinephrine, epinephrine, dopamine) for at least 48 hours during their stay in the ICU and pressure injury development was assessed. The effect of combined use of more than one vasopressor agent on the development of pressure injury was investigated, considering the type and quantity of vasopressors (norepinephrine and dopamine), vasopressor combinations, total duration of infusion, and doses of vasopressors used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: The sample consisted of all medical and surgical patients over 18 who do not have pressure injury upon admission and received one or more vasopressor agent infusions (norepinephrine, epinephrine, dopamine) for at least 48 hours during their stay in the ICU and pressure injury development was assessed. The effect of combined use of more than one vasopressor agent on the development of pressure injury was investigated, considering the type and quantity of vasopressors (norepinephrine and dopamine), vasopressor combinations, total duration of infusion, and doses of vasopressors used.
Study: NCT04471779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disclosure of APOE genotype
Description: Information about risk of Alzheimer's disease will be given to participants based on their APOE genotypes, in addition to Latino ethnicity and family history.
Study: NCT05208385

Intervention type: PROCEDURE
Group type: OTHER
Intervention: video-assisted umbilical closure
Description: video-assisted umbilical closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: video-assisted umbilical closure
Description: video-assisted umbilical closure
Study: NCT06371365

Intervention type: PROCEDURE
Intervention: Free Flap surgery
Description: No intervention, this is an observational study
Study: NCT06089174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra-trail
Description: Questionnaires sent to runners at various pre-race and post-race times (Day3, Day6, Day10, Day14 and Day21)
Study: NCT05992714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses group
Description: Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be watched using VR head device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: white noise group
Description: Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be watched using phone
Study: NCT05351619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oral care bundle implementation
Description: oral care bundle encompasses oral assessment, tooth brushing, oral / lip moisturization, and suctioning oropharyngeal secretions above the cuff.
Study: NCT05447819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplsaty
Description: Patients with the diagnosis of rotator cuff arthropathy (degeneration of the glenohumeral joint and wear or tear of at least one rotator cuff tendon) or degeneration of the glenohumeral joint with severe posterior wear with an indication of a reverse total shoulder arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reverse shoulder arthroplsaty
Description: Patients with the diagnosis of rotator cuff arthropathy (degeneration of the glenohumeral joint and wear or tear of at least one rotator cuff tendon) or degeneration of the glenohumeral joint with severe posterior wear with an indication of a reverse total shoulder arthroplasty
Study: NCT05924815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aficamten
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aficamten
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aficamten
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aficamten
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aficamten-matching Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Oral Tablet
Study: NCT06408545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
Study: NCT05283135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab (Skyrizi) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab (Skyrizi) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.
Study: NCT06424106

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: a variable rate glucagon infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: a variable rate glucose infusion
Study: NCT05855590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 10mg/kg intravenous single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% isotonic saline solution
Description: 100 ml intravenous single dose
Study: NCT06434220

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Baseline model
Description: Model prediction of patient disposition including feature importance scores driving prediction.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fairness-aware model
Description: Model prediction of patient disposition including feature importance scores driving prediction. This model has been tuned to minimize subgroup calibration errors.
Study: NCT05108077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cytokine-induced killer cells
Description: Autologous cytokine-induced killer cells injected intravenously

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment of bladder/renal cancer according to the Clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment of bladder/renal cancer according to the Clinical protocols
Study: NCT05587829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: • Diaphragmatic breathing technique
Description: In supine position, the participant inhales through the mouth for 5 s to expand the abdomen to the maximal level, minimizing movement of the thorax, and performs a long exhalation to maintain a lower abdominal contraction and retroversion of the pelvis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: basic breathing technique
Description: Deep Breathing for 15 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: basic breathing technique
Description: Deep Breathing for 15 minutes
Study: NCT05688033

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
Description: dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
Study: NCT06519344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD20/CD30-CAR-T Cells
Description: Before cell infusion,researchers may decide, based on necessity, whether to administer prophylactic medication,which may include options such as acetaminophen and diphenhydramine, or H1 antihistamines, among others. Subjects are allowed to receive adequate supportive care after anti-CD20/CD30-CAR-T cell infusion,including blood transfusions and blood products, antibiotic therapy, antiemetics, antidiarrheals, analgesice,etc.
Study: NCT05527093

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI 3T and MRI 7T
Description: MRI 3T and MRI 7T before and post epilepsy surgery
Study: NCT05481528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Single oral dose of 400 mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Single oral dose of 400 mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Single oral dose of elinzanetant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Single oral dose of elinzanetant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Single oral dose of elinzanetant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Single oral dose of elinzanetant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of placebo
Study: NCT06074471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided supraclavicular brachial plexus block
Description: Block will be performed in semi-sitting position with head tilted to the opposite side of injection site. linear probe (4-12MHz) (Mindray Digital Ultrasonic Model DP-10 SN 6N-49005130 2014-09. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO.LTD) will be placed parallel to the clavicle in the supraclavicular fossa visualizing the subclavian artery is seen beating above the first rib. A volume of 2 mL lignocaine 2% will be infiltrated subcutaneous before the block. A 20-gauge needle will be advanced in plane aiming to the corner pocket towards the deeper portion of the brachial plexus at the angle between the first rib and the subclavian artery, 10 mL of drug will be injected. Then, the needle will be retracted and advanced at a shallower angle, aiming toward the superficial plexus after negative aspiration another 10 ml will be injected, total drug injected 20 ml (18 mL of drug will be injected with addition to 8mg dexamethasone (2ml))

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided supraclavicular brachial plexus block
Description: Block will be performed in semi-sitting position with head tilted to the opposite side of injection site. linear probe (4-12MHz) (Mindray Digital Ultrasonic Model DP-10 SN 6N-49005130 2014-09. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO.LTD) will be placed parallel to the clavicle in the supraclavicular fossa visualizing the subclavian artery is seen beating above the first rib. A volume of 2 mL lignocaine 2% will be infiltrated subcutaneous before the block. A 20-gauge needle will be advanced in plane aiming to the corner pocket towards the deeper portion of the brachial plexus at the angle between the first rib and the subclavian artery, 10 mL of drug will be injected. Then, the needle will be retracted and advanced at a shallower angle, aiming toward the superficial plexus after negative aspiration another 10 ml will be injected, total drug injected 20 ml (18 mL of drug will be injected with addition to 8mg dexamethasone (2ml))
Study: NCT06382116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed+Cisplatin or Carboplatin
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT05481528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of placebo
Study: NCT04316390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: study drink (two weeks)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hesperidin
Description: study drink + Hesperidin 600 mg (two weeks)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: study drink + Vitamin C 250 mg (two weeks)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hesperidin + Vitamin C
Description: study drink + Hesperidin 600 mg + Vitamin C 250 mg (two weeks)
Study: NCT06291675

Intervention type: DRUG
Intervention: gender-affirming hormone therapy
Description: We are not technically involved in the prescription of gender-affirming hormone therapy. We merely aim at observing effects of GAHT on MRI measured organ lipid content, myocardial mass and function.

Intervention type: DRUG
Intervention: gender-affirming hormone therapy
Description: We are not technically involved in the prescription of gender-affirming hormone therapy. We merely aim at observing effects of GAHT on MRI measured organ lipid content, myocardial mass and function.
Study: NCT06356727

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thermodilution based assessment of coronary microcirculation
Description: Coronary microvascular assessment with the derivation of CFR, IMR and MRR will be performed using a standard pressure/thermodilution guidewire.
Study: NCT05129475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir
Description: Single oral dose of PF-07321332 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir
Description: Single oral dose of PF-07321332 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Single oral dose of ritonavir 100 mg at -12 hours prior to PF-07321332/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours after PF-07321332/ritonavir dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Single oral dose of ritonavir 100 mg at -12 hours prior to PF-07321332/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours after PF-07321332/ritonavir dosing.
Study: NCT05177926

Intervention type: DRUG
Group type: OTHER
Intervention: antiviral prophylaxis with Tenofovir Alafenamide Fumarate
Description: All participants will receive antiviral prophylaxis with Tenofovir Alafenamide Fumarate for preventing of Mother-to-child transmission of HBV
Study: NCT06031935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The patients will receive links to two yoga videos. They will do each of these videos at home for 4 weeks.
Study: NCT04831697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Caregiving Intervention
Description: The multi-caregiving intervention consists of individual-based, social support, and health educator facilitation and includes: a. Storytelling/sharing of experiences (5 minutes); social support and problem solving (15 minutes); Coping strategies (15 minutes); and Structured Diabetes Education and Skills Training (15 minutes). The last 5 minutes will be used to debrief and review goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Enhanced Usual Care Intervention
Description: This is composed of individual-based, health educator-facilitated diabetes education and skills training and general health education and will receive structured diabetes education and skills training as described above (30 minutes) and an additional discussion on general health topics (i.e., back pain, dyspepsia, etc.) (30 minutes).
Study: NCT05170100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NUIG OAB App
Description: An interactive software-delivered 8-week intervention accessed through the patients' mobile device. It provides best-practice behavioural therapy, and delivers evidence-based dietetics, physiotherapy and psychology treatments to reduce the symptoms of overactive bladder.
Study: NCT05025384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure stickers will be applied to one ear in accordance with the NADA protocol acupuncture technique. Application will occur at designated points including Shen Men, Liver, and Lung: in the room with the mother; and potentially during breast feeding, holding, skin to skin contact or bottle feeds. Stickers will remain in place for 24 hours.~At 24 hours, skin will be assessed, and stickers will then be rotated to the opposite ear every 48 - 72 hours if there are no adverse effects such as skin irritation.
Study: NCT05087966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention with Navigation Services
Description: A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
Study: NCT06195631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Checklist for Optimizing Procedural Ergonomics in Endoscopy (SCOPE- E) Bundle
Description: The SCOPE-E bundle is a multicomponent intervention designed to improve endoscopy ergonomics. The bundle is composed of one core intervention and 5 evidence-based implementation strategies which are defined as methods to enhance the adoption, implementation and sustainment of the core intervention. The core intervention is a pre-endoscopy ergonomic time-out checklist. The implementation strategies are endoscopist education, checklist documentation, visual reminders, nursing engagement and leadership support.
Study: NCT06278883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disease Risk Assessment
Description: Undergo personal and family history-based risk assessment and make recommendations for managing risk.